strains has undoubtedly contributed to mortality. Not surprisingly, inappropriate initial empiric antibiotic therapy (IET) for pneumonia or sepsis due to ABC has been associated with heightened mortality. [39] [40] [41] In a recent retrospective review of 1,423 patients hospitalized with sepsis or pneumonia due to ABC, 82.3% of isolates were MDR. 40 MDR-ABC strongly predicted receipt of IET (OR: 5.5, p < 0.001) and IET was associated with higher hospital mortality (OR: 1.8, p < 0.001). 40 In light of the rising incidence of MDR-ABC, 42 a multinational consensus statement was recently published regarding the management and prevention of A. baumannii infections in the ICU.
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Infections Due to ABC in the Hospital Setting
ICU Infections
Most ABC infections occur in hospitalized patients in the ICU, often with multiple comorbidities. Device-related infections (DRI) are typical (i.e., VAP, central venous catheter [CVC]-associated BSI, surgical site infections (SSI), catheter-associated UTIs). The EPIC II point prevalence study in 2007 comprising 75 countries implicated Acinetobacter spp. in 8.8% of all ICU infections, with rates of 19% in Asia and 17% in Eastern Europe. 38 In the SENTRY study from January 2009
to December 2011, ABCs were implicated in 7% of ICU infections in the United States and Europe. 44 Even higher rates of ABC infections have been reported in Latin America 45, 46 and Asia. 17, 47, 48 In a review of Vietnamese pediatric ICUs, ABC was implicated in 18.4% of hospitalacquired infections (HAI); 65% of isolates were carbapenem resistant (CPR). 49 In a prospective study from six hospitals in Iran (2011 Iran ( -2012 , ABC was implicated in 35% of DRI among hospitalized adults. 16 Importantly, 70.5% were CPR.
Hospital-Acquired Pneumonia
ABC is a common cause of ICU-acquired pneumonia, accounting for 8 to 14% of VAP in the United States 50 and Europe, 51 but much higher rates (19% to >50%) in Asia, 48, 52 Latin America, 53 and some Middle Eastern 54 countries. In the United States, rates of VAP due to ABC increased from 4% in 1986 to 7.0% in 2003; no increase was observed for any other gram-negative bacilli. 55 Data from 463 hospitals in the United States from January 2006 to October 2007 implicated A. baumannii in 8.4% of VAP. 50 In a study of 411 cases of VAP from nine European countries, A. baumannii was implicated in 13.9% of cases. 51 In a cohort of 827 cases of VAP in 27 ICUs in Europe, A. baumannii was implicated in 11% of early-onset and 26.5% of late-onset VAP. 56 In Greece and Turkey, ABC was the most common cause of VAP. 56 One prospective study in 34 The rate of increase may be amplified by selection pressure from antimicrobial use, crowding, lack of hygiene, and increased worldwide travel.
24,34
Impact of Antimicrobial Use on Antimicrobial Resistance
Not surprisingly, the use of broad-spectrum antimicrobials has been linked to emergence of antimicrobial resistance. In the early 1990s, the use of imipenem against cephalosporin-resistant Klebsiella pneumoniae was associated with emergence of imipenem-resistant ABC in one New York hospital. Mechanical ventilation and duration of mechanical ventilation 59, 64, 67 Nasogastric tube 62 Resistance to β-Lactams β-Lactamases All A. baumannii strains possess a chromosomal AmpC cephalosporinase that confers resistance to penicillins and early-generation cephalosporins (CEPHS); however, under normal circumstances, resistance to third-and fourthgeneration CEPHS due to AmpC is clinically insignificant.
24,85
Clinically significant resistance may develop via hyperproduction of the AmpC cephalosporinase, 85 the presence of insertion sequences that promote β-lactamase activity, 46 or incorporation of mobile resistance genes.
86
β-Lactamases are categorized based on molecular structure into groups A through D and functionally into three groups (1-3) based on the target enzyme they degrade.
87, 88 Group 1 (class C) cephalosporinases are relatively narrow spectrum. Group 2 (classes A and D) include serine β-lactamases and extended-spectrum β-lactamases (ESBLs) and have a broader spectrum of activity. 88 Group 3 enzymes include metallo β-lactamases (class B), which are potent hydrolyzers of CP and are not inhibited by β-lactamase inhibitors. 88 β-Lactamases of the IMP, VIM, SIM, and NDM-1 families fall within Group 3.
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Extended-Spectrum β-Lactamases
Numerous extended-spectrum β-lactamases (ESBLs) including SHV, TEM, PER, VEB, GES, and CTX-M confer high-grade resistance to all CEPHS. 
Carbapenemases
Many β-lactamases (including ESBLs) may also have hydrolytic activity against CPs via production of carbapenamases (CPE). The emergence of carbapenemases has created a major "hole" in antibiotic coverage against ABC. Carbapenemases include group 2 class D oxacillinases (e.g., OXA enzymes) and class B metallo-β-lactamases (MBLs) (e.g., IMP, VIM, and SIM-1 groups) 34,85 and the newer CPE (i.e., KPC-like; GES-like,
99-102
New Delhi metallo-β-lactamase-1 [NDM-1]).
1,69,103,104
Class D Serine Carbapenemases
Globally, the most common CPE in A. baumannii are the class D serine oxacillinases (OXA), represented by the OXA-23-,
OXA-24-, OXA-58-, and OXA-143-like types that can be encoded on chromosomes or plasmids. In one study, the prevalence of infections due to MDR-ABC fell 2.24-fold after implementing a policy of restricting CP use in the ICU.
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Treatment of Infections Due to Acinetobacter spp.
Nosocomial infections due to ABC have been associated with high mortality rates (particularly with BSI or VAP).
24,34,35
Early appropriate antimicrobial therapy is critical. 
Advanced Generation Cephalosporins
Third-and fourth-generation cephalosporins (e.g., ceftazidime, cefepime) are not reliable for empirical treatment of infections due to ABC. Globally, only 20 to 40% of ABCs are susceptible to expanded spectrum CEPHS. 17 CEPHS should not be used as empirical treatment for ABC infections, but may be considered for susceptible strains.
Sulbactam
Among β-lactamase inhibitors, sulbactam has the greatest bactericidal activity against ABC. 
Fluoroquinolones
Fluoroquinolones may be active against some strains of ABC, but globally, fewer than 30% of ABCs are susceptible to FQs.
17
FQ resistance can emerge via mutations in the quinolone resistance determining regions (QRDR) of gyrA and parC genes and/or by overexpression of efflux pumps.
69
Aminoglycosides
Aminoglycoside resistance among ABCs may emerge via the production of aminoglycoside-modifying enzymes, 16S ribosomal RNA methyltransferase (ArmA), or efflux pumps.
1
In one French study, increased use of amikacin was associated with emergence of amikacin-resistant ABC; decreased amikacin use led to a decrease in case incidence. 172 The Infections Due to Acinetobacter baumannii in the ICU Lynch et al. 315
activity of aminoglycosides against ABC is variable, but resistance rates exceed 60% in most countries.
173
See ►Table 2 for summary of antimicrobial resistance mechanisms among Acinetobacter spp.
Treatment of Infections Due to Acinetobacter spp.
In view of the high incidence of MDR-ABC, initial empirical therapy with combination therapy (typically CP plus colistin) is often employed while awaiting antimicrobial susceptibility results. Optimal therapy is not clear, as randomized, controlled studies are lacking. In the next sections, we will discuss antibiotics that are often used either as monotherapy or part of combination therapy for MDR-ABC.
Polymyxins (Colistin)
Polymyxins ( [178] [179] [180] However, colistin has relatively poor PK/PD properties, and it may be difficult to achieve high enough serum concentrations quickly. 155 CMS (a prodrug) has to be converted to the active form (colistin) in the plasma, and concentrations may be suboptimal for 2 to 3 days until a steady state is achieved; thus, a loading dose is recommended.
1 One in vitro study suggested that achievement of serum levels more than 1 mg/L within 1 hour had significant bactericidal activity.
181
Studies reporting efficacy of colistin monotherapy for ABC infections are limited. In a prospective study of 35 episodes of VAP due to MDR-ABC, patients were treated with imipenem (n ¼ 14) versus colistin (n ¼ 21) based on susceptibility testing.
182 Cure rates were 57% in both groups; in-hospital mortality rates were similar (64 and 62%, respectively). The Table 2 Common mechanisms of antimicrobial resistance in Acinetobacter spp.
Resistance mechanism Target antimicrobial References
Enzymatic inactivation or modification of antimicrobials 185 These various retrospective studies are inadequate to assess the role or benefit (if any) of combination therapy or the optimal agents to use for serious infections due to ABC. Aerosolized (inhaled) colistin has been used in patients with cystic fibrosis and as adjunctive therapy for nosocomial pneumonia due to ABC, but data are limited to nonrandomized, retrospective studies.
1, 186 One randomized open-label trial compared the efficacy of nebulized CMS (plus IV colistin) for 100 patients with gram-negative VAP, 60% of which were due to ABC. Microbiological outcome was better with nebulized plus IV therapy (60.9%) compared with 38.2% among IV CMS only group (p ¼ À 0.03). Importantly, clinical outcomes were similar (51.0 vs. 53.1%, p ¼ 0.94). Further, there were more episodes of bronchospasm in the nebulized plus IV therapy group (7.8 vs. 2.0%, respectively, p ¼ 0.36). The clinical benefit of nebulized CMS to treat VAP has not been established. Resistance to colistin may develop. 185 Plasmid-mediated resistance via mcr-1 gene among Enterobacteriaceae was first reported China, 187 and human cases of E. coli or Enterobacteriaceae expressing mcr-1 were described shortly thereafter in Switzerland, 188, 189 Canada, 190 and Singapore. 191 The mcr-1 gene has not yet been identified in Acinetobacter spp., but it is feasible that in time, MDR Acinetobacter could acquire this resistance mechanism. Colistin heteroresistance may also occur. 155 Colistin-resistant ABCs appear to have reduced fitness and less virulence, 192 including a decreased ability to form biofilms.
193
Tigecycline
Tigecycline, a semisynthetic derivative of minocycline, has excellent in vitro activity against MDR-ABC (including CPR strains). 194, 195 
Eravacycline
Eravacycline is a novel fluorocycline of the tetracycline class with broad-spectrum activity against gram-negative and gram-positive aerobic and anaerobic pathogens. 202 Like tigecycline, eravacycline is not affected by many of the tetracycline-specific resistance mechanisms found in gram-negative bacteria, including acquired efflux systems and ribosomal protection. 202 Eravacycline is two-to fourfold more active (reduced MIC 90 ) than tigecycline versus A. baumannii. 203 Whether this increased in vitro activity translates into greater clinical efficacy is not known. Infections Due to Acinetobacter baumannii in the ICU Lynch et al. 317
Other Antimicrobial Agents
Rifampin
Rifampin exhibits activity against MDR-ABC in vitro and in animal models.
1 In animal models, the combination of rifampin plus colistin may confer additive or synergic bactericidal activity. 1 However, in two randomized trials of serious MDR-ABC infections, the combination of rifampin plus colistin was no better than colistin alone. 204, 205 The role of rifampin as part of combination therapy has not been established.
Other Combination Therapy Using Colistin
Combination therapy has been studied to treat MDR-ABC, particularly with colistin as part of the combination. 171, [183] [184] [185] 206 In vitro studies have shown that synergy may be achieved with combinations of colistin, carbapenems, and rifampicin, in both colistin-S and colistin-R strains of Acinetobacter spp. 207, 208 In a retrospective multicenter study, Batirel et al evaluated 250 BSIs due to extremely drug resistant (XDR)-ABC (all isolates were susceptible to colistin). 183 Groups included colistin monotherapy (n ¼ 36);
and colistin þ other agents (n ¼ 43). Complete response rates, 14-day and in-hospital survival, and microbiologic eradication were significantly higher in the combination group, but no differences could be seen between the various combinations. 183 A multicenter prospective observational study in Spain of 101 patients with MDR-ABC infections demonstrated no significant difference in 30-day mortality between combination therapy with colistin versus monotherapy with various agents, predominantly a CP. 184 Cheng et al prospectively studied 176 episodes of bacteremia due to XDR-A. baumannii in three hospitals in Taiwan. 206 Among infections with tigecycline MIC > 2 mg/L, combination therapy with colistin plus tigecycline was associated with significantly higher 14-day mortality and more breakthrough bacteremias compared with colistin plus CP.
206
The addition of glycopeptides (agents with gram-positive activity) to colistin has displayed synergy against ABC in vitro. 155 However, clinical studies are limited, and data are conflicting.
209,210
Novel Agents
It is obvious that new agents are needed to treat ABC infections. Anti-GNB compounds that belong to old classes of agents such as β-lactams, CPs, FQs, and β-lactamase inhibitors are in development, as are novel classes.
211-214
Ceftazidime/avibactam contains an older third-generation CEPH (i.e., ceftazidime), with avibactam, a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. [215] [216] [217] Limited data suggest that the addition of avibactam does not improve the activity of ceftazidime against Acinetobacter spp. 215 Ceftolozane is a novel cephalosporin with a chemical structure similar to that of ceftazidime, with the exception of a modified side chain at the three-position of the cephem nucleus, which confers potent antipseudomonal activity. 
